Your browser doesn't support javascript.
loading
Modification of the ALBI-PLT Score for the Prediction of High-risk Varices.
Inoue-Yuri, Minako; Enomoto, Hirayuki; Wakabayashi, Ichiro; Yuri, Yukihisa; Aizawa, Nobuhiro; Ikeda, Naoto; Takashima, Tomoyuki; Fujiwara, Aoi; Yoshioka, Ryota; Kawata, Shoki; Yoshihara, Kohei; Ota, Shogo; Nakano, Ryota; Shiomi, Hideyuki; Nishimura, Takashi; Nishiguchi, Shuhei; Iijima, Hiroko.
Affiliation
  • Inoue-Yuri M; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Enomoto H; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Wakabayashi I; Department of Environmental and Preventive Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Yuri Y; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Aizawa N; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Ikeda N; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Takashima T; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Fujiwara A; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Yoshioka R; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Kawata S; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Yoshihara K; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Ota S; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Nakano R; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Shiomi H; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Nishimura T; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
  • Nishiguchi S; Department of Gastroenterology, Kano General Hospital, Osaka, Japan.
  • Iijima H; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
In Vivo ; 36(3): 1360-1366, 2022.
Article in En | MEDLINE | ID: mdl-35478164
ABSTRACT
BACKGROUND/

AIM:

A new scoring system [albumin-bilirubin-platelet (ALBI-PLT) score] was reported for identifying cirrhotic patients without high-risk varices (HRV), and patients with ALBI grade 1 (≤-2.60) and a platelet count over 150×109/l were shown to have a low risk of having HRV. The present study modified the cut-off values of the variables in the ALBI-PLT score. PATIENTS AND

METHODS:

Among a total of 338 patients with chronic liver diseases, possible cut-off values of the ALBI score and the platelet count were determined by analyzing the first-half group (training cohort N=169) with the receiver operating characteristic (ROC) method. The utility of the determined values was evaluated in the second-half group (validation cohort N=169) and total cohort (N=338). In addition, the utility of the modified cut-off values was evaluated in patients with compensated cirrhosis (cirrhotic cohort N=87).

RESULTS:

Possible cut-off values of the ALBI score and platelet count were found to be -2.36 and 114×109/l, respectively. In the training cohort, these cut-off values provided a higher ratio of avoiding esophagogastroduodenoscopy than the original ALBI-PLT score (53.3% vs. 25.4%, p<0.01). Consistent results were observed in the validation cohort (28.4% vs. 15.4%, p<0.01), total cohort (40.8% vs. 20.4%, p<0.01), and cirrhotic cohort (32.2% vs. 11.5%, p<0.01). However, the missing ratio of patients with the HRV was not significantly increased in any cohort studied.

CONCLUSION:

Modification of the ALBI-PLT score may be useful for predicting patients without HRV.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Varicose Veins / Bilirubin Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: In Vivo Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Varicose Veins / Bilirubin Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: In Vivo Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: